O	0	2	Up
O	3	5	to
O	6	8	15
O	8	9	-
O	9	13	year
O	14	22	clinical
O	23	29	follow
O	29	30	-
O	30	32	up
O	33	35	of
O	36	37	a
O	38	43	pilot
O	44	49	Phase
O	50	53	III
O	54	67	immunotherapy
O	68	73	study
O	74	76	in
O	77	82	stage
O	83	85	II
O	86	92	breast
O	93	99	cancer
O	100	108	patients
O	109	114	using
B-intervention	115	123	oxidized
I-intervention	124	130	mannan
I-intervention	130	131	-
I-intervention	131	135	MUC1
O	135	136	.

O	137	146	Targeting
O	147	155	antigens
O	156	158	to
O	159	168	dendritic
O	169	173	cell
O	174	183	receptors
O	184	187	has
O	188	196	recently
O	197	203	become
O	204	205	a
O	206	213	popular
O	214	222	approach
O	223	225	to
O	226	234	inducing
O	235	244	effective
O	245	251	immune
O	252	261	responses
O	262	269	against
O	270	276	cancer
O	277	285	antigens
O	285	286	.

O	287	293	Almost
O	294	296	20
O	297	302	years
O	303	306	ago
O	306	307	,
O	308	315	however
O	315	316	,
O	317	319	we
O	320	332	demonstrated
O	333	337	that
O	338	347	targeting
O	348	351	the
O	352	359	mannose
O	360	368	receptor
O	369	371	on
O	372	383	macrophages
O	384	387	and
O	388	397	dendritic
O	398	403	cells
O	404	409	leads
O	410	412	to
O	413	419	strong
O	420	428	cellular
O	429	435	immune
O	436	445	responses
O	445	446	.

O	447	449	We
O	450	459	conducted
O	460	468	numerous
O	469	474	human
O	475	483	clinical
O	484	490	trials
O	491	504	demonstrating
O	505	508	the
O	509	522	effectiveness
O	523	525	of
O	526	534	oxidized
O	535	541	mannan
O	541	542	-
O	542	546	MUC1
O	547	548	(
O	548	549	M
O	549	550	-
O	550	552	FP
O	552	553	)
O	554	556	in
O	557	561	MUC1
O	561	562	(
O	562	563	+
O	563	564	)
O	565	579	adenocarcinoma
O	580	588	patients
O	588	589	.

O	590	592	In
O	593	596	one
O	597	602	trial
O	602	603	,
O	604	607	the
O	608	609	5
O	609	610	-
O	610	611	8
O	611	612	-
O	612	616	year
O	617	623	follow
O	623	624	-
O	624	626	up
O	627	629	of
B-eligibility	630	636	breast
I-eligibility	637	643	cancer
I-eligibility	644	652	patients
I-eligibility	653	663	vaccinated
I-eligibility	664	668	with
I-eligibility	669	670	M
I-eligibility	670	671	-
I-eligibility	671	673	FP
O	674	677	was
O	678	687	published
O	688	698	previously
O	698	699	;
O	700	702	we
O	703	706	now
O	707	713	report
O	714	718	here
O	719	722	the
O	723	725	12
O	725	726	-
O	726	728	15
O	728	729	-
O	729	733	year
O	734	740	follow
O	740	741	-
O	741	743	up
O	743	744	.

O	745	752	Details
O	753	762	regarding
O	763	766	the
O	767	778	preparation
O	779	781	of
O	782	785	the
O	786	793	vaccine
O	793	794	,
O	795	804	inclusion
O	805	808	and
O	809	818	exclusion
O	819	827	criteria
O	827	828	,
O	829	842	immunotherapy
O	843	846	and
O	847	853	follow
O	853	854	-
O	854	856	up
O	857	865	schedule
O	865	866	,
O	867	871	were
O	872	881	published
O	882	892	previously
O	892	893	.

O	894	897	The
O	898	904	follow
O	904	905	-
O	905	907	up
O	908	910	at
O	911	913	12
O	913	914	-
O	914	916	15
O	917	922	years
O	923	929	showed
O	930	934	that
O	935	938	the
B-outcome	939	949	recurrence
I-outcome	950	954	rate
O	955	957	in
O	958	966	patients
O	967	976	receiving
B-control	977	984	placebo
O	985	988	was
B-cv-bin-percent	989	991	60
I-cv-bin-percent	991	992	%
O	993	994	(
B-cv-bin-abs	994	998	nine
O	999	1001	of
B-control-participants	1002	1004	15
O	1004	1005	)
O	1005	1006	.

O	1007	1009	In
O	1010	1015	those
O	1016	1025	receiving
O	1026	1039	immunotherapy
O	1040	1041	(
O	1041	1042	M
O	1042	1043	-
O	1043	1045	FP
O	1045	1046	)
O	1046	1047	,
O	1048	1051	the
O	1052	1056	rate
O	1057	1060	was
B-iv-bin-percent	1061	1063	12
I-iv-bin-percent	1063	1064	.
I-iv-bin-percent	1064	1065	5
I-iv-bin-percent	1065	1066	%
O	1067	1068	(
B-iv-bin-abs	1068	1071	two
O	1072	1074	of
B-intervention-participants	1075	1077	16
O	1077	1078	)
O	1078	1079	.

O	1080	1083	The
B-outcome	1084	1088	time
I-outcome	1089	1091	of
I-outcome	1092	1102	recurrence
O	1103	1105	in
O	1106	1109	the
O	1110	1117	placebo
O	1118	1123	group
O	1124	1130	ranged
O	1131	1135	from
O	1136	1137	7
O	1138	1140	to
O	1141	1144	180
O	1145	1151	months
O	1152	1153	(
O	1153	1157	mean
O	1157	1158	:
B-cv-cont-mean	1159	1161	65
I-cv-cont-mean	1161	1162	.
I-cv-cont-mean	1162	1163	8
I-cv-cont-mean	1164	1170	months
O	1170	1171	)
O	1172	1175	and
O	1176	1178	in
O	1179	1182	the
O	1183	1186	two
O	1187	1195	patients
O	1196	1198	of
O	1199	1202	the
O	1203	1210	vaccine
O	1211	1216	group
O	1216	1217	,
O	1218	1221	the
B-outcome	1222	1232	recurrence
I-outcome	1233	1241	appeared
O	1242	1244	at
O	1245	1247	95
O	1248	1251	and
O	1252	1255	141
O	1256	1262	months
O	1263	1264	(
O	1264	1268	mean
O	1268	1269	:
B-iv-cont-mean	1270	1273	118
I-iv-cont-mean	1274	1280	months
O	1280	1281	)
O	1282	1287	after
O	1288	1295	surgery
O	1295	1296	.

O	1297	1302	These
O	1303	1311	findings
O	1312	1315	are
O	1316	1329	statistically
O	1330	1341	significant
O	1342	1343	(
O	1343	1344	p
O	1345	1346	=
O	1347	1348	0
O	1348	1349	.
O	1349	1351	02
O	1352	1355	for
O	1356	1364	survival
O	1365	1368	and
O	1369	1370	p
O	1371	1372	=
O	1373	1374	0
O	1374	1375	.
O	1375	1378	009
O	1379	1382	for
O	1383	1393	percentage
O	1394	1396	of
O	1397	1405	patients
O	1406	1412	cancer
O	1412	1413	-
O	1413	1417	free
O	1417	1418	)
O	1418	1419	.

O	1420	1423	All
O	1424	1432	patients
O	1433	1441	injected
O	1442	1446	with
O	1447	1448	M
O	1448	1449	-
O	1449	1451	FP
O	1452	1458	showed
O	1459	1461	no
O	1462	1470	evidence
O	1471	1473	of
B-outcome	1474	1479	toxic
I-outcome	1480	1487	effects
O	1488	1490	or
O	1491	1496	signs
O	1497	1499	of
O	1500	1512	autoimmunity
O	1513	1519	during
O	1520	1523	the
O	1524	1526	12
O	1526	1527	-
O	1527	1529	15
O	1529	1530	-
O	1530	1534	year
O	1535	1541	follow
O	1541	1542	-
O	1542	1544	up
O	1544	1545	.

O	1546	1549	The
O	1550	1561	preliminary
O	1562	1570	evidence
O	1571	1580	indicates
O	1581	1585	that
O	1586	1587	M
O	1587	1588	-
O	1588	1590	FP
O	1591	1593	is
O	1594	1604	beneficial
O	1605	1607	in
O	1608	1611	the
B-outcome	1612	1619	overall
I-outcome	1620	1628	survival
O	1629	1631	of
O	1632	1637	early
O	1637	1638	-
O	1638	1643	stage
O	1644	1650	breast
O	1651	1657	cancer
O	1658	1666	patients
O	1666	1667	.

O	1668	1672	This
O	1673	1677	long
O	1677	1678	-
O	1678	1682	term
O	1683	1691	clinical
O	1692	1698	follow
O	1698	1699	-
O	1699	1701	up
O	1702	1704	of
O	1705	1713	patients
O	1714	1722	strongly
O	1723	1731	supports
O	1732	1735	the
O	1736	1745	necessity
O	1746	1749	for
O	1750	1751	a
O	1752	1757	large
O	1758	1763	Phase
O	1764	1767	III
O	1768	1773	study
O	1774	1776	of
O	1777	1783	direct
O	1784	1785	M
O	1785	1786	-
O	1786	1788	FP
O	1789	1798	injection
O	1799	1801	in
O	1802	1807	early
O	1807	1808	-
O	1808	1813	stage
O	1814	1820	breast
O	1821	1827	cancer
O	1828	1836	patients
O	1836	1837	,
O	1838	1840	to
O	1841	1849	evaluate
O	1850	1863	immunotherapy
O	1864	1866	as
O	1867	1869	an
O	1870	1878	adjuvant
O	1879	1888	treatment
O	1889	1892	for
O	1893	1899	breast
O	1900	1906	cancer
O	1906	1907	.
